Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study
Open Access
- 15 December 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1330421
Abstract
Introduction: Direct oral anticoagulants (DOACs) have become widely used in clinical practice for preventing thromboembolic events. Point-of-care testing methods, particularly those based on urine samples, offer a promising approach for rapid and accurate assessment of DOAC presence. This pilot study aims to evaluate the utility of a urine-based DOAC dipstick test as a point-of-care tool for identifying DOAB presence in acute ischemic stroke (AIS) or transient ischemic attack (TIA) patients.Patients and methods: This prospective pilot study included patients with AIS/TIA eligible for DOAC-measurement. After exclusion of 3 patients, 23 patients with DOAC-intake (DOAC group; factor-Xa-inhibitors; n = 23) and 21 patients without DOAC-intake (control-group) remained for analyses. The urine-based DOAC dipstick test and parallel blood-based specific DOAC-level assessment were performed in all patients. Time-intervals of sampling urine/blood sampling and result of DOAC-test were recorded to analyze a potential time benefit based on dipstick evaluation.Results: The urine-based DOAC dipstick test demonstrated high sensitivity (100%) and specificity (100%), correctly identifying all patients with anticoagulatory activity due to DOAC intake (i.e., anti-Xalevel ≥30 ng/mL). Moreover, the visual readout of the test provided semiquantitative information on drug-specific anti-Xa levels, showing a sensitivity of 83% and specificity of 93% to detect anti-Xa levels ≥120 ng/mL. The dipstick test exhibited a median time-benefit of 2:25 h compared to standard blood-based DOAC-level testing.Discussion: The results of this pilot study underline the efficacy of urine-based point-of-care testing as a rapid and reliable method for assessing DOAC presence in patients with acute ischemic stroke.Conclusion: The value of this tool for clinical decision-making in stroke management needs to be established in future trials.Clinical Trial Registration: Clinicaltrails.org identifier [NCT06037200].Keywords
This publication has 32 references indexed in Scilit:
- Emergency Coagulation Assessment During Treatment With Direct Oral AnticoagulantsStroke, 2017
- Evolution of the Modified Rankin Scale and Its Use in Future Stroke TrialsStroke, 2017
- Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-StrokeStroke, 2017
- Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulantsCritical Care, 2017
- Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?International Journal of Stroke, 2016
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation.2013
- Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral AnticoagulantsStroke, 2009
- Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of DetectionBiometrical Journal, 2008